We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Brain Signal Determines Stroke Outcome

By HospiMedica staff writers
Posted on 30 Nov 2005
A specific signal in brain cells may determine whether stroke patients live or die, suggesting that new therapies for stroke victims could be developed by controlling the signaling pathway, according to a new study published in the November 13, 2005, online issue of Nature Medicine.

Scientists at the University of Heidelberg (Germany) discovered that damaged and dying brain cells are using an internal "communications network” known as the NF-kB signaling pathway. More...
Evidence in nerve cells had suggested this pathway could trigger apoptosis. To clarify the function of the pathway, the scientists developed a "conditional knockout” mouse with a stroke-like condition in which a protein called IKK2 activated the pathway. This allowed them to shut down the NF-kB molecule at any time in neurons. Meanwhile, another group of investigators at the University of Ulm (Germany), working in parallel, had generated two additional mouse models that allowed the reversible repression or activation of IKK2 at any time in neurons.

By combining their findings, the researchers were able to obtain a clear picture of IKKs's role after a stroke. Mice with the hyperactive form of IKK2 in neurons and too much NF-kB signaling suffer more damage than normal and far more cells die. However, if the IKK2 signal is blocked, damaged cells stay alive and appear to recover even when the blocking is done a few hours after the stroke. Moreover, the effects are long-term: neurons in the damaged tissues were still alive several days after the stroke.

"The unique advantage of this system is that we can specifically induce or block this signaling pathway at virtually any time and selectively in neurons,” said Thomas Wirth, University of Ulm. He noted that the same effects could be achieved by blocking the IKK2 pathway with a small artificial molecule, which is what a drug would have to do.





Related Links:
University of Heidelberg
University of Ulm

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.